Buffett followers
Buffett followers
No personal profile
0Follow
5Followers
0Topic
0Badge

XPeng Misses on Guidance and Losses Deepen – Is There Any Hope Left?

$XPeng Inc.(XPEV)$ Released Its 2026 Q2 Earnings This Afternoon; Overall Performance Was Mediocre, and U.S. Pre-Market Shares Dropped Nearly 4% After the Report. The results show that for the second quarter of 2026, revenue came in at RMB 19.74 billion, up 8% year-over-year and 51.5% quarter-over-quarter, missing the consensus estimate of RMB 20.2 billion. Gross margin was 20.7%, an increase of 3.4 percentage points from the same period last year and above the consensus estimate of 19.15%. On an adjusted basis, the comparable net loss was RMB -1.237 billion, far worse than the expected loss of RMB -0.767 billion. The profit shortfall was mainly due to a swing from gain to loss on a long-term investment, creating a paper loss of app
XPeng Misses on Guidance and Losses Deepen – Is There Any Hope Left?

Xiaomi notches fourth straight gain — is the tide turning?

$XIAOMI-W(01810)$'s stock price rose nearly 4% today, continuing its winning streak since the release of its earnings report, with total gains approaching 11%. On the news front, Xiaomi just released its Q2 earnings report two days ago. Against the backdrop of high memory prices and a pressured consumer terminal market, Xiaomi's core smartphone business remained resilient, with gross margins in the handset business delivering a surprise upside that beat market expectations. In addition, Xiaomi just unveiled its new-generation humanoid robot "CyberOne" at the 2026 World Robot Conference, marking its first public appearance. The robot has already entered automotive factories for "internships" — at the self-tapping screw station, its
Xiaomi notches fourth straight gain — is the tide turning?

Alibaba stock crashes 10% after $80B placement – should you bottom-fish?

This morning, $Alibaba(BABA)$'s stock price plunged over 10% at one point, nearing the HK$110 level, which dragged the Hang Seng Tech Index down by 2.5%. On the news front, Alibaba Group raised approximately HK$80 billion (US$10.2 billion) through the largest stock placement in Hong Kong market history, underscoring the company's determination to raise and deploy substantial funds in its bid for global AI leadership. The giant, which has pivoted from online retail to the AI arena, placed 710 million new shares at HK$112.7 each, an 8.4% discount to last Friday's closing price in Hong Kong. In terms of dilution, based on public data estimating Alibaba's total outstanding Hong Kong shares at about 20.4 billion, the newly issued 710 mi
Alibaba stock crashes 10% after $80B placement – should you bottom-fish?

Plunge! How Did Alibaba's Earnings Really Turn Out?

$Alibaba(BABA)$ released its first-quarter fiscal 2026 earnings report, with revenue of RMB 268.95 billion, roughly in line with market estimates (RMB 268.52 billion). However, adjusted ADS earnings came in at only RMB 8.52, far below the year-ago figure of RMB 14.75 and the estimate of RMB 11.28. Adjusted net income was RMB 20.72 billion, down 38% year-over-year and missing expectations. Adjusted EBITDA was RMB 39.14 billion, down 14% year-over-year but slightly above estimates. Other income for the quarter was RMB 28.8 billion, significantly below the estimate of RMB 61.15 billion. The company repurchased approximately 13.4 million shares for a total of $162 million. Profit contribution from Ant Group was $230 million. Following
Plunge! How Did Alibaba's Earnings Really Turn Out?

Clueless? Duan Yongping got caught buying Moderna at the peak.

Duan Yongping, the legendary investor widely known as "Da Dao Wu Xing Wo You Xing" on Investment Platform, has reportedly suffered a major loss on $Moderna, Inc.(MRNA)$, the recent star of U.S. biotech stocks. He first built a position in MRNA back in 2021, when the stock was trading near its peak, and even posted on Investment Platform about his interest in the name. He added to his position multiple times afterward, but eventually liquidated his entire holding at $28.5 per share. Based on rough estimates, Duan lost nearly $24 million on this investment, with a staggering -60% return. Even a top-tier investor can stumble outside his circle of competence. Does his recent avoidance of tech stocks suggest a limited grasp of the secto
Clueless? Duan Yongping got caught buying Moderna at the peak.

NetEase Q2 earnings released: revenue up, profit down. Where is it headed next?

NetEase reported Q2 net revenue of RMB 30.1 billion, up 7.9% year-over-year and beating market expectations of RMB 29.54 billion. Gross profit came in at RMB 21.2 billion, rising 17.5% year-over-year and surpassing the consensus estimate of RMB 19.57 billion. In contrast, adjusted diluted net income per ADS from operating activities was RMB 12.02, falling short of the market's expected RMB 15.59. On a segment basis, online game services revenue reached RMB 25.02 billion, exceeding expectations by RMB 740 million, while innovation and other businesses generated RMB 1.64 billion in revenue, in line with market forecasts. On the bottom line, net profit attributable to shareholders of the company was RMB 7.0 billion, down nearly 18.6% from RMB 8.6 billion in the same period last year. Followin
NetEase Q2 earnings released: revenue up, profit down. Where is it headed next?

Moderna's 177% surge ignites HK biotech rally. Is it still time to buy in?

Today at the opening, Hong Kong-listed innovative drug stocks surged, with $石药集团(01093)$ jumping 14.28%, $药明康德(02359)$ rising 5% to hit a record high, and $百济神州(06160)$ climbing over 3.58%. On the news front, the rally was boosted by a breakthrough in R&D from a U.S. pharmaceutical company. On August 19, $Moderna, Inc.(MRNA)$ and Merck jointly announced the successful Phase III trial of their partnered mRNA vaccine, sending Moderna's stock soaring 176.97% in a single day and adding $40 billion to its market capitalization. This marks the first success
Moderna's 177% surge ignites HK biotech rally. Is it still time to buy in?

Kuaishou released its second-quarter earnings, posting the slowest revenue growth in its history.

Kuaishou's Q2 results broadly met market expectations. According to the company's financial report, total revenue in the second quarter grew 1.4% year-over-year to RMB 35.54 billion, marking the slowest growth rate in its history and broadly in line with the Bloomberg consensus estimate of RMB 35.51 billion. Net profit and adjusted net profit came in at RMB 3.15 billion and RMB 3.91 billion, respectively, both slightly exceeding market expectations. However, both net profit and adjusted net profit posted significant declines, mainly due to a sharp 34.7% increase in R&D spending to RMB 4.58 billion, which compressed profit margins. Nonetheless, company management reiterated its commitment to deepening AI investment as a long-term strategic direction. Notably, Kuaishou's Kling AI deliver
Kuaishou released its second-quarter earnings, posting the slowest revenue growth in its history.

Xiaomi jumps nearly 7% post-earnings. Time for a turnaround?

Today, $小米集团-W(01810)$ stock price surged, at one point rising over 5%, driven by a surprising counter-trend growth in its smartphone business gross margin. Previously, against the backdrop of high memory prices and a pressured consumer terminal market, market expectations for Xiaomi's smartphone business were relatively low. After the earnings report was released, the numbers showed that Xiaomi's smartphone revenue declined 7.5% year-over-year, and shipments also decreased significantly by 26.5% compared to the same period last year. However, the primary reason for this was the company's optimization of its product mix, which involved cutting shipments of mid-to-low-end models. The effects of this product premiumization strategy
Xiaomi jumps nearly 7% post-earnings. Time for a turnaround?

Zhipu's shares tumble — fair value adjustment or a golden chance to buy the dip?

Today, $Z.AI(02513)$ at one point plunged over 16%, with its share price approaching the key HK$1,000 level. $MINIMAX-W(00100)$ also tumbled more than 12% at one point, with its stock price briefly falling to near HK$282. Domestic large-model AI stocks may be facing a critical test. On the news front, Goldman Sachs and UBS have issued "Hold" and "Buy" ratings on $Z.AI(02513)$, respectively, with no notable negative catalysts apparent. However, on August 17, Daiwa released a research report pointing out that the market reaction to $Z.AI(02513)$'s GLM-5.3
Zhipu's shares tumble — fair value adjustment or a golden chance to buy the dip?

Go to Tiger App to see more news